Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice

Breast Cancer Research and Treatment

Volumn 110, Issue 2, 2008, Pages 283-295

  Wang, Wen Bo ^a   Zhou, Yu Lin ^a   Heng, De Feng ^b   Miao, Chuan Hui ^b   Cao, Ying Lin ^c  

^a Xiamen Maternity and Child Health Care Hospital   (China)

^b Zaozhuang Municipal Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Antitumor activity; Apoptosis; Canstatin; hTERT; Targeted gene expression; TRAIL

Indexed keywords

CANSTATIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LIVER TOXICITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; TELOMERASE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 44849136781     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9731-4     Document Type: Article

References (49)

1. Seltzer V (2000) Cancer in women: prevention and early detection. J Womens Health Gend Based Med 9:483-488
2. Ganten TM, Koschny R, Sykora J et al (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12(8):2640-2646
3. Seeger H, Huober J, Wallwiener D et al (2004) Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Metab Res Horm 36:277-280
4. Amornmarn R, Bui MM (2000) Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy. Ann Clin Labo Sci 30(1):33-40
5. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
6. Pitti RM, Marsters SA, Ruppert S et al (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690
7. Guo Y, Chen C, Zheng Y et al (2005) Novel anti-human DR5 mono-clonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 280(51):41940-41952
8. Lu X, Arbiser JL, West J et al (2004) Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalig-nant cells. Am J Pathol 165:1613-1620
9. Yao GH, Hou YY (2006) Recent advances for research on anti-tumor effects of TNF-related apoptosis inducing ligand. Wei Sheng Yan Jiu 35:115-117
10. Griffith TS, Lynch DH (1998) TRAIL: a molecule with multiple receptor and control mechanisms. Curr Opin Immunol 10:559-563
11. Kischkel FC, Lawrence DA, Chuntharapai A et al (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611-620
12. Cretney E, Takeda K, Smyth MJ et al (2007) Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39(2):280-286
13. Jo M, Kim TH, Seol DW et al (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567
14. Zheng S-J, Wang P, Tsabary G et al (2004) Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113(11):58-64
15. Liu XS, Zhu Y, Han WN et al (2003) Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2. Hybrid Hybridomics 22(2):121-125
16. Sandra F, Hendarmin L, Nakamura S et al (2006) Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 42(4):415-420
17. Chaudhari BR, Murphy RF, Agrawal DK et al (2006) Following the TRAIL to apoptosis. Immunol Res 35(3):249-262
18. Kamphaus GD, Colorado PC, Panka DJ et al (2000) Canstatin, a novel matrix-derived inhibitor angiogenesis and tumor growth. J Biol Chem 275:1209-1215
19. Panka DJ, Mier JW (2003) Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 278:37632-37636
20. Lin T et al (2002) Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effect on primary human hepatocytes. Cancer Res 62:3620-3625
21. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS (2003) TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171:1526-1533
22. Suhara T, Mano T, Oliveira BE et al (2001) Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res 89:13-19
23. Kagawa S, He C, Gu J et al (2001) Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61:3330-3338
24. He G, Luo J, Zhang T et al (2003) Cloning and expression of human canstatin and its purification and bioactivity. Wei Sheng Wu Xue Bao 43:607-612
25. Takakura M, Kyo S, Kanaya T et al (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551-557
26. Koga S, Hirohata S, Kondo Y et al (2000) A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11:1397-1406
27. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
28. Kagawa S et al (2000) Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 60:1157-1161
29. Jacob D, Davis J, Zhu H et al (2004) Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 10:3535-3541
30. Zhu H, Zhang L, Huang X et al (2004) Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 9:666-673
31. Gu J, Andreeff M, Roth JA, Fang B (2002) hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Therapy 9:30-37
32. Ivkovic-Kapic T, Knelevic-Usaj S, Panjkovic M et al (2006) Immunohistochemical analysis of angiogenesis in invasive ductal breast carcinoma with correlations to clinicopathological factor. Vojnosanit Pregl 63(7):635-642
33. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49
34. Adams JM, Cory S (1998) The Bcl-2 protein family:arbiters of cell survival. Science 281:1322-1326
35. Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305-1308
36. Hetts SW (1998) To die or not to die: an overview of apoptosis and its role in disease. JAMA 279:300-307
37. Folkman J (1995) Angiogenesis inhibitors generated by tumors. Mol Med 1:120-122
38. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 86:353-364
39. Folkman J (1996) Fighting cancer by attacking its blood supply. Sci Am 275:150-154
40. Colorado PC, Torre A, Kamphaus G et al (2000) Antiangiogenic cues from vascular basement membrane collagen. Cancer Res 60:2520-2526
41. Lin T, Huang X, Gu J et al (2002) Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 21:8020-8028
42. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL (2000) Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 165:2886-2894
43. Singh TR, Shankar S, Chen X et al (2003) Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63:5390-5400
44. Chinnaiyan Am, Prasad U, Shankar S et al (2000) Combined effect of TRAIL and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97:1754-1759
45. Chang JY, Zhang X, Komaki R, Cheung R, Fang B (2006) Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 64:1482-1494
46. Zhou L, Yan MX, Yao M, Feng YJ (2005) Antitumor effect of endothelial progenitor cells with TRAIL gene transfection on ovarian carcinoma xenografts in nude mice. Ai Zheng 24:1312-1316
47. Malin S, Yuki H, Hikaru S et al (2005) Function of endogenous inhibitors of angiogenesis as endothelium specific tumor suppressors. PNAS 102:2934-2939
48. Narazaki M, Tosato G et al (2006) Canstatin: an inhibitor of angio-genesis and tumor growth revisited. Cancer J 12(2):110-112
49. Song JS (2004) Activity of the human telomerase catalytic subunit (hTERT) gene promoter could be increased by the SV40 enhancer. Biosci Biotechnol Biochem 68:1634-1639